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Abstract
The goal of this article was to investigate the diagnosis, treatment and mechanisms of the leukemoid reaction (LKR) 
14 15 associated with transitional cell carcinoma. A 64-year-old male patient presented with anuria. Color ultrasound 
imaging 15 16 revealed a large bladder tumor. Digital radiography and computerized tomography of the chest, abdomen 
and pelvis 16 17 revealed only bilateral hydronephrosis, but did not reveal any metastasis. The pre-operative white 
blood cell count in 17 18 the peripheral blood consistently increased to 58,400/mm3 while neutrophil granulocyte count 
was 54,900/mm3, without 18 19 fever. Radical cystectomy and construction of bilateral cutaneous ureterostomy was 
performed. The histological diagnosis 19 20 was transitional cell carcinoma, Grade 3. Granulocyte colony-stimulating factor 
(G-CSF) staining was positive in tumor 20 21 cells. Results: After surgery, the leukocyte value became nearly normal. At 
3 months later, patient was admitted to our 21 22 hospital with the complaints of the left leg edema, diagnosed as pelvic 
lymph node metestasis. Patient died of systemic 22 23 metastasis within 6 months after the cystectomy. Bladder cancer 
associated with LKR, though rare, is considered highly 23 24 malignant, difficult to diagnose and as having poor prog
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Introduction
The term leukemoid reaction (LKR) describes an 
elevated white blood cell (WBC) count (>50 × 109/L) 
or leukocytosis that is a physiological response to stress 
or infection (as opposed to a primary blood malignancy, 
such as leukemia). A LKR is typically a response to an 
underlying medical issue such as drugs, Hemorrhage, 
infections, Asplenia, Diabetic ketoacidosis, Organ necrosis, 
etc., Bladder tumors are commonly seen in urinary surgery, 
but reports on LKR caused by bladder carcinoma are rare. 
One such patient was admitted to and treated recently at 
our hospital; the analytic report follows.
Case Report
A 64-year-old male was admitted to our hospital 20 days 
after electroscission for bladder tumor recurrence with a 
chief complaint of anuria for 1 day. 3 years prior, he had 
received cystoscopic examination for 1 month due to a 
painless gross total hematuria and a solitary waterweed-like 
neoplasm was discovered. He was diagnosed with a bladder 
tumor and treated with transurethral electroscission. The 
post-operative pathological report revealed a solitary 
uroepithelium carcinoma of the bladder (Degree II). 
Post-operative bladder irrigation with 30 mg mitomycin 
was performed once weekly for 6 weeks, then biweekly 
for 12 weeks and then once monthly for 2 years. He was 
rehospitalized for bladder tumor recurrence 20 days ago 
and was treated with electroscission for the bladder tumor. 
The post-operative pathological report showed invasive 
uroepithelium carcinoma of the bladder. He was discharged 
from the hospital after recovery. Hematuria appeared again 
and worsened and then he was anuric for 1 day prior to 
admittance. Ultrasonic examination in another hospital 
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revealed bilateral hydronephrosis and bilateral ureter 
expansion and he was readmitted to our hospital. Physical 
examination revealed body temperature was 37.1°C, pulse 
was 71 beats/min, respiratory rate was 16 breaths/min 
and BP was 122/83 mmHg. Palpation revealed no swollen 
superficial lymph nodes, no bulging in costal spinal angle and 
lumbar region, no percussion pain in bilateral costal spinal 
angle and no sign of psoas major stimulation. There was no 
tenderness or masses in the suprapubic region. Auscultation 
of the heart and lungs revealed no abnormality. Laboratory 
findings after admission were WBC count of 26.2 × 109/L, 
neutrophil count of 23.0 × 109/L, serum creatinine 
level of 1460 μmol/L, granulocyte colony-stimulating 
factor (G-CSF) of 4032 ng/L, immunoglobulin (Ig) G 
16.4 g/L, serum Igκ light chain of 13.9 g/L, urine Igκ light 
chain of 294 mg/L and urine IgΥ light chain of 234 mg/L. 
Pathological examination of bone marrow aspirated from 
the right anterior superior iliac spine revealed active 
proliferation of myeloid tissue and granulation hyperplasia. 
Color ultrasound examination of the abdomen revealed 
no obvious abnormality in the lymph nodes in the liver, 
gallbladder, spleen, pancreas and retroperitoneum. 
Computed tomography (CT) scanning revealed (1) local 
thickening in the posterior wall of the urinary bladder, which 
was considered possible evidence of recurrence after the 
bladder carcinoma operation; and (2) prostate calcification. 
Chest radiography revealed aortosclerosis and lung pleural 
thickening on both sides.
Immediately after admittance, ultrasound-guided 
percutaneous catheterized drainage for hydronephrosis of 
the right kidney was performed as emergency treatment. 
Laboratory examination revealed that serum creatinine 
decreased to 245 μmol/L and the WBC count continued 
to rise (to a maximum of 58.4 × 109/L) after the antibiotics 
treatment of 3 days as did the neutrophilic granulocyte 
count (to a maximum of 54.9 × 109/L). The patient had no 
fever. Consultation with hematologists gave a diagnosis of 
LKR, after bone marrow aspiration and determination of the 
content of bone marrow deoxyribonucleic acid (DNA) to 
exclude the possibilities of infection and leukemia. Radical 
cystectomy and cutaneous bilateral ureterostomy were 
performed under general anesthesia. The post-operative 
pathological report showed invasive uroepithelium 
carcinoma of the bladder (Degree III) with involvement of 
every layer of the bladder and seminal vesicles. Metastasis 
was not found in the lower rectal margin of the bladder, 
bilateral ureters or adipose tissue lymph nodes [Figure 1]. 
Immunohistochemistry (IHC) revealed overexpression of 
G-CSF in cancer cells [Figure 2]. Examination 2 weeks after 
the operation revealed the WBC count was 13.7 × 109/L 
and the neutrophil count was 9.8 × 109/L. Patient presented 
with the left waist abdomen pain accompanies edema of 
the left lower limb 3 months after discharge. Laboratory 
examination showed the WBC count was 44.5 × 109/L 
and the neutrophil count was 39.21 × 109/L. CT scanning 
revealed the possibility of lymph node metastasis within 
and behind the left iliacus. Left lower back pain and left 
lower limb edema were ameliorated after treatment with 
an argon-helium knife and reexamination showed a WBC 
count of 39.0 × 109/L, a neutrophil count of 34.73 × 109/L 
and appearance of juvenile cells. At 3 months after leaving 
the hospital, patient died of systemic metastasis.
Discussion
LKR describes an elevated WBC count or leukocytosis 
that is a physiological response to stress or infection (as 
opposed to a primary blood malignancy, such as leukemia). 
The course can be either acute or chronic. Primary 
diseases may be acute or chronic infection, malignant 
cancer, hematological disorder, chemical injuries, etc., In 
terms of characterizing LKRs by cell type involved, there 
Figure 1: Pathological section at low magnification (×100) 
with H and E stain. Pathological report: Invasive uroepithelium 
carcinoma of the bladder (Degree III) with involvement of every 
layer of bladder and seminal vesicle
Figure 2: Pathological section at high magnification (×400) with 
immunohistochemistry. Immunohistochemistry reveals overexpression 
of granulocyte colony‑stimulating factor in cancer cells
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are neutrophilic, eosinophilic, basophilic, monocellular, 
lymphocytic, erythroleukemic and mixed lineage LKRs, 
of which neutrophilic LKR is most commonly seen. 
Conventionally, a leukocytosis exceeding 50,000 WBC/mm3 
with a significant increase in early neutrophil precursors is 
referred to as a LKR. The peripheral blood smear may show 
a mix of early mature neutrophil precursors, in contrast to 
the immature forms typically seen in acute leukemia. The 
bone marrow in a LKR, if examined, may be hypercellular, 
but is otherwise typically unremarkable. This is named 
leukocytosis neutrophilic LKR, which was seen in this case 
report. This disease should be differentially diagnosed with 
leukemia. In general, the major manifestation of LKR is 
abnormal serum WBC with restriction to one cell type, 
not involving erythrocytes or megakaryocytes; therefore, 
patients do not suffer from anemia or thrombocytopenia. 
Changes in the myelogram are not prominent and there 
are no symptoms of leukemia other than hyperplasia and 
left shift. In cellular morphology, toxic granulation and 
vacuoles often appear in LKR, without cell abnormalities. 
Primary diseases often exist and the hemogram values 
return to normal when the primary disease is treated. 
There is no tissue or organ invasion and neutrophil alkaline 
phosphatase (NAP) remains at a normal level or increases. 
In cases of leukemia, toxic granulation and vacuoles seldom 
appear and cell abnormalities exist in most cases, often 
with tissue and organ invasion and NAP decreasing or 
disappearing.
As early as 1973, Block and Whitmore[1] reported one case 
of bladder cancer accompanied by LKR, thrombocythemia 
and hypercalcemia. Since then, 48 cases of bladder cancer 
with LKR have been reported in Japan and the disease 
was identified by high levels of invasion and metastasis. 
Its prognosis was extremely poor and life expectancy of 
most patients was less than 1 year.[2] In the case reported 
here, local recurrence and lymph node metastasis appeared 
3 months after the operation. The patient died of systemic 
metastasis 6 months later. In 1990, Ito et al.[3] discovered 
that G-CSF may be produced in bladder cancer. In 1993, 
Satoh et al.[4] reported one case of squamous cell carcinoma 
of the bladder with leukocytosis, in which the count of 
WBC reached a maximum of 50.3 × 109/L. The patient 
died of systemic metastasis 9 months after the operation. 
Furthermore, it was found that the patient’s serum G-CSF 
level was 4928 ng/L. Furthermore, hepatic metastatic tumors 
also generate G-CSF, which is identified by the IHC analysis, 
indicating that G-CSF secretion in bladder tumor resulted 
in paraneoplastic LKR.
However, whether G-CSF can accelerate proliferation of 
bladder cancer cells is still controversial. In 1994, Sato 
et al.[5] found that the serum G-CSF level increased, which 
further induced leukocytosis in a patient with invasive 
bladder carcinoma, with no gene rearrangement and 
amplification of G-CSF. They also did not find the G-CSF 
receptor in cancer cells. Hence, indirect promotion of 
proliferation of the bladder carcinoma by G-CSF could 
not be proved. However, as reported by Tachibana et al.,[6] 
high-levels of expression of G-CSF messenger ribonucleic 
acid (mRNA) and G-CSF receptor mRNA were found 
in cancer cells of patients with LKR bladder carcinoma. 
Proliferation in bladder carcinoma was induced in vitro 
by exogenous G-CSF and could be inhibited by anti 
G-CSF antibodies, which demonstrated that generation of 
G-CSF closely correlated with the proliferation of bladder 
carcinoma. Ohmi et al.[7] found that, in the presence of 
peripheral blood mononuclear cells, recombinant human 
G-CSF (rhG-CSF) strongly promotes proliferation of 
KK47 cells (derived from a transitional cell bladder 
carcinoma) in a dose-independent manner.
Levels of basic fibroblast growth factor (basic FGF) appear 
to be important to the effective dose of G-CSF. It was 
considered that rhG-CSF might promote proliferation of 
KK47 cells by accelerating production of basic FGF. In 2004, 
Chakraborty et al.[8] found that in bladder carcinoma samples 
with G-CSF and granulocyte colony-stimulating factor 
receptor (G-CSFR) expression, expression of integrin-β1 
protein was increased. Furthermore, expression of G-CSF, 
G-CSFR and integrin-β1 was similarly increased in normal 
bladder mucosa that was distant from bladder carcinoma. 
In the 5637 human bladder carcinoma cell line, G-CSFR 
promotes integrin-β1 adherence to fibronectin and laminin. 
Further studies proved that expression of G-CSF/G-CSFR 
in bladder carcinoma promotes adherence and invasion 
of cancer cells by a mechanism involving integrin-β1.[9] 
Transfecting TCC-SUP and 5637 cell lines with plasmids 
encoding G-CSFR, G-CSF/G-CSFR promoted proliferation 
of TCC-SUP-GR and anti G-CSF antibody accelerated 
apoptosis of 5637 glucocorticoid receptor (GR) cells. 
5637 GR cells implanted in nude mice induced formation 
of a huge subcutaneous tumor, demonstrating that the 
autocrine (paracrine) pathway of G-CSF/G-CSFR promotes 
survival and growth of bladder cancer cells.[10] An increasing 
number of case reports have shown rapid tumor recurrence 
and systemic metastasis, with extremely poor prognoses. 
LKR and G-CSF have been widely accepted as markers 
useful in estimating prognosis for patients with bladder 
transitional cell carcinoma.[11,12]
Bladder carcinoma has a high rate of recurrence and 
progression. Although many relevant molecular markers 
have been identified, molecular markers of bladder 
cancer with both specificity and sensitivity have not been 
determined. Research in recent years has concentrated on 
such candidates as p53, Rb, cyclin D, p27Kip1, fibroblast 
growth factor receptor-3, cadherin, survivin, aurora, matrix 
metalloproteinase enzymes (MMP) vascular endothelial 
growth factor and DNA methylation, among others. 
Molecular markers will become an effective tool in the 
diagnosis and prognosis of bladder carcinoma, although 
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for bladder carcinoma in different stages or degrees, one 
particular marker may be more or less useful. Detection of 
G-CSF also will contribute to estimating the prognosis of 
bladder carcinoma.
Hu et al.[13] recently used streptavidin-granulocyte-macrophage 
colony-stimulating factor (SA-GM-CSF) to irrigate the 
bladder of a mouse in vivo tumor model and discovered 
that the morbidity of mice with bladder carcinoma treated 
with SA-GM-CSF decreased from 100% to 37.5%. Further, 
70% of mice treated with SA-GM-CSF were immune 
to wild MB49 cancer cells administered in a secondary 
irrigation of the bladder, indicating that SA-GM-CSF had 
a potent anti-tumor effect. Zhang et al.[14] administered 
SA-GM-CSF to mouse metastatic bladder cancer models 
and lung metastatic bladder cancer models. Higher numbers 
of CD4 and CD8 cells were found in the area of tumors and 
in the peripheral blood of treated animals and proliferation 
of cancer cells were prominently inhibited. The mice were 
immune to secondary injections of MB49 cancer cells. Shi 
et al.[15] demonstrated that sequential use of MB49 tumor 
vaccine modified with GM-CSF and IL-2 effectively induced 
a specific anti-tumor immune response.
LKR, a rare paraneoplastic reaction in patients with bladder 
carcinoma, indicates a high degree of malignancy, high 
probability of metastasis and recurrence and wretched 
prognosis. Analyses of bone marrow and DNA can 
exclude leukemia and testing of WBC count and levels 
of G-CSF contributes to diagnosis and estimation of 
prognosis. Appearance of LKR correlates with expression 
of G-CSF/G-CSFR and promotes survival and growth 
of bladder cancer cells. In future studies, drugs blocking 
G-CSF/G-CSFR signaling can be used to further improve 
prognosis and promote curative effects.
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